National Survey Reveals The Compromises Overactive Bladder Sufferers Endure (NAPSA)—Accordingto the results of Ne More Compromises!, a national survey commissioned by the National Women’s Health Resource Center (NWHRC), complications of overactive bladder (OAB) and drying side effects associated with OAB medications (constipation, dry mouth, dry skin) are leading causes for dissatisfaction among sufferers. In fact, 50 percent of OAB patients discontinue their medication after the first month of therapy, choosing instead to live with the symptoms of OAB (urge urinary incontinence, urgency, frequency and nocturia), a condition that affects more than 33 million Americans. Although the survey did not establish a causal relationship, women suffering from moderate to severe OABreported the following: * They’re less likely to exercise than those who do not experience drying side effects. * More than three-quarters worry about personal hygiene. “In this day and age, a woman in the primeof herlife should feel empowered to embrace a happy, healthy and active lifestyle,” said Amy Niles, president and CEO of the NWHRC. “It’s unsettling to think a condition affecting so many women would cause sufferers to compromise their way of life. These survey results clearly underscore the need for continued research in the area of overactive bladder and new treatment options for the women whosuffer.” The good newsis there continues to be new options. The FDA has recently approved the first and only transdermal treatment for OAB with symptoms of urge urinary incontinence, urgency and frequency. OxyTROL” is a thin, flexible, clear patch that is applied to the abdomen, hip or buttock with convenient twice weekly dosing, and has drying side effects similar to placebo. OXxYTROL™ may not be for everyone. The most common adverse events occurring with OxyYTROL” were application site reactions, dry mouth, constipation, diarrhea, dysuria and abnormal vision. If you would like to learn more, talk to your doctor, visit www.OXYTROL.com orcall the toll-free number 1-888OXYTROL to receive a complimentary brochure. Watson Pharma, Inc., provided financial support for the survey, which was conducted by Harris Interactive on behalf of the National Women’s Health Resource Center. Harris Interactive conducted online interviews with 1,228 women—898 who experienced symptoms commonly associated with OAB and 330 who did not report these symptoms.
